22 Percent Quarterly Revenue Growth Stocks to Buy in November 2026: 5 Names on the Watchlist
- November 12, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Bajaj Finance Rs 1,079. Globus Spirits Rs 729.35. Hero Rs 5,345. Ipca Labs Rs 1,938. Vijaya Rs 1,424. NSE closing prices, 11 Nov 2026.
Quick Answer
Five 22 percent quarterly revenue growth stocks to buy on the November 2026 watchlist are Bajaj Finance, Globus Spirits, Hero MotoCorp, Ipca Laboratories and Vijaya Diagnostic Centre. All five grew revenue in their latest full year, and all five also grew net profit. Hero MotoCorp has both the lowest P/E at 19.33 and the highest return on equity at 26.57%. Check each valuation against your own risk appetite before acting.
The 22 percent quarterly revenue growth stocks to buy in November 2026 start with five listed names: Bajaj Finance, Globus Spirits, Hero MotoCorp, Ipca Laboratories and Vijaya Diagnostic Centre. These five companies each grew revenue by about 20% to 23% in the September 2026 quarter compared with a year earlier. Bajaj Finance and Hero MotoCorp are part of the Nifty 50 index, Bajaj Finance is part of the Nifty Fin Service index and Hero MotoCorp is part of the Nifty Auto index.
This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these 22 percent quarterly revenue growth stocks to buy to a portfolio. All prices are NSE closing prices of 11 November 2026, and financials come from company filings.
Click Here – Get Free Investment Predictions
Which Are the Best 22 Percent Quarterly Revenue Growth Stocks to Buy in November 2026?
The best 22 percent quarterly revenue growth stocks to buy in November 2026 for a watchlist are Bajaj Finance, Globus Spirits, Hero MotoCorp, Ipca Laboratories and Vijaya Diagnostic Centre. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.
| Company | CMP (Rs) | Market Cap | P/E | ROE | Dividend Yield |
|---|---|---|---|---|---|
| Bajaj Finance | 1,079 | Rs 5,71,076 crore | 25.88 | 17.61% | 0.65% |
| Globus Spirits | 729.35 | Rs 2,324 crore | 23.28 | 8.41% | 0.00% |
| Hero MotoCorp | 5,345 | Rs 1,06,086 crore | 19.33 | 26.57% | 3.49% |
| Ipca Laboratories | 1,938 | Rs 48,860 crore | 35.53 | 14.15% | 0.31% |
| Vijaya Diagnostic Centre | 1,424 | Rs 15,086 crore | 80.48 | 18.07% | 0.14% |
On valuation, Globus Spirits and Hero MotoCorp trade below the industry P/E; Ipca Laboratories sits close to it; Bajaj Finance and Vijaya Diagnostic Centre carry a premium. Valuation is the first filter for any 22 percent quarterly revenue growth stocks to buy list, and it is covered again in the risk section.
Why These 22 Percent Quarterly Revenue Growth Stocks to Buy Are in Focus
In this list, FY26 net profit and revenue both grew for every company, and quarterly profit in the September 2026 quarter was higher than a year earlier for all five. The list covers a large consumer lender, a spirits and ethanol maker, the country’s largest two-wheeler maker, a pharma company and a diagnostics chain. Investors comparing the best stocks with 22 percent quarterly revenue growth in India usually check whether sales growth turns into profit, how the shares are valued and how much debt the company carries.
Bajaj Finance: The NBFC Leader Among 22 Percent Quarterly Revenue Growth Stocks to Buy
Bajaj Finance is India’s largest non-banking finance company by market value, lending across consumer, SME and mortgage segments. Its market capitalisation is Rs 5,71,076 crore, the share price is Rs 1,079 and the P/E of 25.88 compares with an industry P/E of 16.13.
Over FY26, net profit rose 15.2% to Rs 19,332 crore on revenue of Rs 81,990 crore, which was up 19.1%. The latest quarter, the September 2026 quarter, brought revenue of Rs 24,576 crore, up 22.9% year on year, and net profit of Rs 6,367 crore, up 28.7%.
Return on equity is 17.61%, and the dividend yield is 0.65%. Promoters hold 54.67%, foreign institutions 19.79% and domestic institutions 17.05% as of September 2026. Domestic institutional holding has risen from 14.47% to 17.05% over the last year.
Globus Spirits: A Distillery With Ethanol Exposure Among 22 Percent Quarterly Revenue Growth Stocks to Buy
Globus Spirits is a distiller producing grain-based neutral spirits, bottled brands and ethanol. The stock trades at Rs 729.35 with a market capitalisation of Rs 2,324 crore and a P/E of 23.28, against an industry P/E of 49.38.
FY26 revenue rose 6.9% to Rs 2,723 crore and net profit rose 315.4% to Rs 91.0 crore. In the June 2026 quarter, revenue grew 20.9% year on year to Rs 1,154 crore, while net profit grew 50.7% to Rs 27.3 crore.
Return on equity is 8.41%, debt-to-equity is 0.48, and the dividend yield is negligible. Promoters hold 46.74%, foreign institutions 13.58% and domestic institutions 8.58% as of September 2026. Foreign institutional holding has risen from 6.47% to 13.58% over the last year.
Check 22 Percent Quarterly Revenue Growth Stocks Live on the Univest Screener
Hero MotoCorp: The Volume Two-Wheeler Leader Among 22 Percent Quarterly Revenue Growth Stocks to Buy
Hero MotoCorp is India’s largest two-wheeler maker by volume, with a broad commuter and scooter range. At Rs 5,345, the stock has a market capitalisation of Rs 1,06,086 crore and trades at 19.33 times earnings, while the industry P/E is 23.63.
Reported numbers show FY26 revenue of Rs 48,469 crore, up 15.5% year on year, with net profit at Rs 5,776 crore, up 32.0%. The September 2026 quarter added revenue of Rs 15,172 crore (up 21.8%) and net profit of Rs 1,861 crore (up 40.8%).
Return on equity is 26.57%, debt-to-equity is 0.04, and the dividend yield is 3.49%. Promoters hold 34.72%, foreign institutions 32.22% and domestic institutions 23.94% as of September 2026. Foreign institutional holding has risen from 28.76% to 32.22% over the last year.
Ipca Laboratories: The Formulations and API Name Among 22 Percent Quarterly Revenue Growth Stocks to Buy
Ipca Laboratories is a pharma company making formulations and active ingredients, known for anti-malarial and pain-management products. Its market capitalisation is Rs 48,860 crore, the share price is Rs 1,938 and the P/E of 35.53 compares with an industry P/E of 37.65.
Over FY26, net profit rose 51.3% to Rs 1,191 crore on revenue of Rs 9,821 crore, which was up 8.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 2,813 crore, up 20.2% year on year, and net profit of Rs 423 crore, up 80.4%.
Return on equity is 14.15%, debt-to-equity is 0.10, and the dividend yield is 0.31%. Promoters hold 44.72%, foreign institutions 11.53% and domestic institutions 36.59% as of September 2026. Foreign institutional holding has risen from 10.43% to 11.53% over the last year.
Vijaya Diagnostic Centre: The South India Diagnostics Name Among 22 Percent Quarterly Revenue Growth Stocks to Buy
Vijaya Diagnostic Centre is a south India focused diagnostics chain with strong radiology and pathology services. The stock trades at Rs 1,424 with a market capitalisation of Rs 15,086 crore and a P/E of 80.48, against an industry P/E of 61.50.
FY26 revenue rose 19.3% to Rs 835 crore and net profit rose 20.3% to Rs 173 crore. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit grew 37.6% to Rs 53.1 crore.
Return on equity is 18.07%, debt-to-equity is 0.44, and the dividend yield is 0.14%. Promoters hold 52.46%, foreign institutions 10.66% and domestic institutions 32.50% as of September 2026. Domestic institutional holding has risen from 25.34% to 32.50% over the last year. A point to keep in view: at a P/E of 80.48, expectations are already high.
Download the Univest iOS App or Univest Android App to track these 22 percent quarterly revenue growth stocks live and get daily stock recommendations.
Growth Snapshot: Latest Full Year and Latest Quarter
The table compares year-on-year growth in revenue and net profit for all five 22 percent quarterly revenue growth stocks, using filed results.
| Company | Full-Year Revenue Growth | Full-Year Profit Growth | Latest Quarter | Quarter Revenue Growth | Quarter Profit Growth |
|---|---|---|---|---|---|
| Bajaj Finance | 19.1% | 15.2% | Sep 2026 | 22.9% | 28.7% |
| Globus Spirits | 6.9% | 315.4% | Jun 2026 | 20.9% | 50.7% |
| Hero MotoCorp | 15.5% | 32.0% | Sep 2026 | 21.8% | 40.8% |
| Ipca Laboratories | 8.7% | 51.3% | Jun 2026 | 20.2% | 80.4% |
| Vijaya Diagnostic Centre | 19.3% | 20.3% | Jun 2026 | 22.8% | 37.6% |
Factors That Move 22 Percent Quarterly Revenue Growth Stocks to Buy
Four factors tend to drive 22 percent quarterly revenue growth stocks, and each one is worth checking before a purchase.
- Quarterly growth: Revenue rose about 20% to 23% year on year.
- Dividends: Hero MotoCorp yields about 3.5%.
- Return on equity: Hero MotoCorp leads at about 27%.
- Valuation: P/E runs from about 19 to 80.
Risks to Keep in Mind Before Buying 22 Percent Quarterly Revenue Growth Stocks
The first risk is that Vijaya Diagnostic Centre trades at a P/E near 80 while Hero MotoCorp trades near 19, so expectations differ widely. The second is that Bajaj Finance carries the highest borrowings of the five as a lender, and Globus Spirits is valued at only about Rs 2,300 crore. Check results every quarter.
On the numbers, Vijaya Diagnostic Centre trades at the highest P/E on this list at 80.48, so its earnings need to keep growing to support the price. 22 Percent Quarterly Revenue Growth stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.
How to Choose 22 Percent Quarterly Revenue Growth Stocks to Buy
- Compare growth: Ipca Laboratories grew FY26 profit by about 51%.
- Check P/E: Hero MotoCorp trades lowest.
- Read ROE: Hero MotoCorp leads.
- Spread sectors: Mix lending, spirits, two-wheelers, pharma and diagnostics.
How to Invest in 22 Percent Quarterly Revenue Growth Stocks
- Shortlist two or three companies from this list that match your risk appetite.
- Open the Univest Screener and compare P/E, ROE and debt for each stock.
- Check the latest quarterly results and shareholding pattern on NSE or BSE.
- Decide an amount you can hold for three to five years and split it into two or three purchases.
- Review the holding after every quarterly result instead of reacting to daily price moves.
Conclusion
Hero MotoCorp offers both the lowest P/E on this list at 19.33 and the highest return on equity at 26.57%, and Globus Spirits posted the fastest net profit growth in its latest full year at 315.4%. Among the best 22 percent quarterly revenue growth stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these 22 percent quarterly revenue growth stocks to buy.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on 22 Percent Quarterly Revenue Growth Stocks to Buy
Which are the best 22 percent quarterly revenue growth stocks to buy in November 2026?
Ans. The five 22 percent quarterly revenue growth stocks on the November 2026 watchlist are Bajaj Finance, Globus Spirits, Hero MotoCorp, Ipca Laboratories and Vijaya Diagnostic Centre. Hero MotoCorp has both the lowest P/E at 19.33 and the highest ROE at 26.57%, and Globus Spirits grew net profit 315.4% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.
Is Bajaj Finance a good stock to buy from this 22 Percent Quarterly Revenue Growth list?
Ans. Bajaj Finance is the largest company on this list with a market capitalisation of Rs 5,71,076 crore and a P/E of 25.88 against an industry P/E of 16.13. Its FY26 revenue rose 19.1% and net profit rose 15.2%, with return on equity at 17.61%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.
Are these 22 percent quarterly revenue growth stocks expensive right now?
Ans. Valuations vary across the group. Bajaj Finance trades at a P/E of 25.88, Globus Spirits trades at a P/E of 23.28, Hero MotoCorp trades at a P/E of 19.33, Ipca Laboratories trades at a P/E of 35.53, Vijaya Diagnostic Centre trades at a P/E of 80.48, against industry multiples ranging from 16.13 to 61.50. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.
Which of these 22 percent quarterly revenue growth stocks pay a dividend?
Ans. Dividend yields on this list are Bajaj Finance 0.65%, Hero MotoCorp 3.49%, Ipca Laboratories 0.31%, Vijaya Diagnostic Centre 0.14%. Yields differ widely across the group, so check payout history and earnings cover before relying on any of them for income, since payouts can change with company profits.
Which stock on this list has the highest return on equity?
Ans. Hero MotoCorp has the highest ROE on this list at 26.57%, followed by Vijaya Diagnostic Centre at 18.07% and Bajaj Finance at 17.61%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.
What are the risks of investing in 22 percent quarterly revenue growth stocks?
Ans. The main risks are one very high valuation, borrowings at the lender and thin trading at the smallest name. On this list, Vijaya Diagnostic Centre trades at the highest P/E of 80.48, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.
How can I invest in 22 percent quarterly revenue growth stocks in India?
Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.
